SAM
TEVA icon

Silvercrest Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Silvercrest Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,539
Closed -$346K – 941
2024
Q1 		$346K Hold
24,539
– – ﹤0.01% 780
2023
Q4 		$256K Buy
24,539
+11,449
+87% +$107K ﹤0.01% 766
2023
Q3 		$134K Buy
+13,090
New +$122K ﹤0.01% 804
2016
Q4 		– Sell
-11,069
Closed -$509K – 584
2016
Q3 		$509K Buy
11,069
+621
+6% +$32.4K 0.01% 406
2016
Q2 		$525K Sell
10,448
-171
-2% -$9.1K 0.01% 400
2016
Q1 		$568K Sell
10,619
-30,000
-74% -$1.76M 0.01% 394
2015
Q4 		$2.67M Buy
40,619
+900
+2% +$55.6K 0.04% 267
2015
Q3 		$2.24M Hold
39,719
– – 0.03% 259
2015
Q2 		$2.35M Sell
39,719
-224
-0.6% -$13.8K 0.03% 281
2015
Q1 		$2.49M Sell
39,943
-49
-0.1% -$2.85K 0.04% 248
2014
Q4 		$2.3M Buy
39,992
+59
+0.1% +$3.29K 0.03% 261
2014
Q3 		$2.15M Sell
39,933
-449
-1% -$23.8K 0.03% 263
2014
Q2 		$2.12M Buy
40,382
+1
+0% +$51 0.03% 265
2014
Q1 		$2.13M Buy
40,381
+1
+0% +$46 0.03% 258
2013
Q4 		$1.62M Sell
40,380
-499
-1% -$19.6K 0.03% 279
2013
Q3 		$1.54M Buy
40,879
+1
+0% +$39 0.03% 274
2013
Q2 		$1.6M Buy
+40,878
New +$1.59M 0.03% 264

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Silvercrest Asset Management's TEVA Position: Q2 2024 in Review

Silvercrest Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2024, closing a stake of 24,539 shares — an estimated $346K sold.

Silvercrest Asset Management first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $2.67M in Q4 2015. 533 funds tracked by Wall St. Rank hold TEVA as of Q2 2024.

  • Silvercrest Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Silvercrest Asset Management sold 24,539 Teva Pharmaceuticals shares in Q2 2024, an estimated $346K.
  • Silvercrest Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • Silvercrest Asset Management's Teva Pharmaceuticals position peaked at $2.67M in Q4 2015.
  • 533 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2024.

Based on Silvercrest Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.